Pay in 4 interest-free payments of $5.56 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
If you want the branded version, you can request it through Hers, but the price will be much higher
Byrne, Giovanni Targher Liver International .2025;[Epub] CrossRef Discovery of Highly Potent, Selective, and Liver-Targeted THR- Agonists for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis Ju Liang, Yipei Gu, Liuyu Hu, Hui Qu, Nana Li, Chaoyue Xia, Lei Feng, Li Qin, Li Hai, Yaxi Yang, Ying Leng, Bing Zhou Journal of Medicinal Chemistry .2025
doi: 10.1210/me.2006-0178 73 RoedSNNhrACWismannPIversenHBruner-OsborneHKnudsenSMet al
Julie Shtraks is literally the best doctor ever, and just overall an amazing person
Yet while reducing cardiovascular disease by treating high cholesterol, high blood pressure, and diabetes is standard practice, the concept of treating obesity to reduce cardiovascular complications has been hampered by the lack of evidence that lifestyle or pharmacologic interventions for overweight or obesity improve cardiovascular outcomes, said Michael Lincoff, M.D., SELECTs lead author and vice chair for research in Cleveland Clinics Department of Cardiovascular Medicine
patients seeking alternative provider relationships, medication options, compounding pharmacies, or genetic-informed personalization may benefit from exploring other pathways
